|
|
Vol. 15.08 – 25 March, 2024
|
|
|
|
|
|
|
|
Scientists defined endogenous CD8 T cell responses to a conserved DNAJB1-PRKACA gene fusion in fibrolamellar carcinoma patients and evaluated fusion-specific T cell receptors for use in cellular immunotherapies. [Cell Reports Medicine]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Human adipose-derived stem cells and human umbilical vein cells were prepared as spheroids, which were encapsulated in gelatin methacryloyl hydrogels to fabricate a 3D pre-vascularized tissue.
[Biofabrication]
|
|
|
|
|
|
The attenuated tumour targeting Salmonella typhimurium SL7207 strain was modified to carry chromosomally integrated shRNA expression cassettes at the xylA locus.
[Cell & Bioscience]
|
|
|
|
|
|
Overexpression of insulin-like growth factor 1 (IGF-1) via recombinant adeno-associated viral vectors would improve osteochondral repair and reduce parameters of early perifocal osteoarthrisis in sheep after six months in vivo.
[American Journal Of Sports Medicine]
|
|
|
|
|
|
Scientists sought to enhance the in vivo longevity of CAR-Vδ2 T cells by modulating ex vivo manufacturing conditions and selecting an optimal CAR costimulatory domain.
[Cytotherapy]
|
|
|
|
|
|
CAR’TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR, revealed increased and prolonged anti-tumor activity in vitro, particularly in case of low target antigen expression.
[Molecular Therapy Oncology]
|
|
|
|
|
|
In order to optimize the RNAi conditions for PVD neuron, scientists fed the worm strains with E. coli HT115 bacteria expressing dsRNA against mec-3, hpo-30, and tiam-1, whose loss of function were known to show dendrite morphology defects in PVD neuron. [PLOS One]
|
|
|
|
|
|
|
|
The authors present key advances in the design of nanoscale drug delivery systems, such as polymer–drug conjugates, liposomes, nanoparticles, micelles, for subcutaneous delivery.
[Nature Reviews Bioengineering]
|
|
|
|
|
|
Investigators evaluated the use of various nanomaterials in the production of CAR-T cells, genetic modification, and in vivo delivery. [Advanced Healthcare Materials]
|
|
|
|
|
|
|
|
The risks of early death in the trials of Johnson & Johnson, Legend Biotech’s Carvykti, Bristol Myers Squibb, and 2seventyBio’s Abcema were not a significant concern for the FDA’s Oncologic Drugs Advisory Committee, which voted to support the approvals of the CAR-T therapies as earlier lines of treatment for multiple myeloma. [BioSpace]
|
|
|
|
|
|
A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as CAR T-cell therapy that was pioneered in the United States. A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000. [Nature News]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
University of Manitoba – Winnipeg City, Manitoba, Canada
|
|
|
|
|
|
|
University of Colorado – Aurora, Colorado, United States
|
|
|
|
|
|
|
University of Sydney – Sydney, Australia
|
|
|
|
|
|
|
UC Davis – Davis, California, United States
|
|
|
|
|
|
|
BC Provincial Health Services Authority – Vancouver, British Columbia, Canada
|
|
|
|
|
|